~ Caliway Biopharmaceuticals to Present Latest R&D Progress and Pipeline Development at 2025 BIO International Convention

Caliway Biopharmaceuticals (TWSE: 6919) has announced its participation in the highly anticipated 2025 BIO International Convention, set to take place from June 16 to 19 in Boston, U.S.A. The company's Vice President, April Yuan, will be delivering an oral presentation on June 17, highlighting Caliway's latest advancements in research and development as well as updates on their pipeline.

The presentation will focus on CBL-514, a first-in-class injectable drug candidate for targeted fat reduction in large areas. This includes its development for multiple indications such as subcutaneous fat reduction, cellulite, and Dercum's disease.

In addition to these updates, Caliway will also be sharing preclinical data on a potential new indication for CBL-514: weight rebound management through a combination therapy with GLP-1 receptor agonists. This is significant as post-discontinuation weight rebound has become a major concern for patients using GLP-1 treatments globally. Studies have shown that only 10% of patients are able to maintain weight loss after stopping GLP-1 therapy.

Based on Caliway's preclinical data, co-administration of CBL-514 with GLP-1 significantly reduced post-discontinuation body weight regain and fat replenishment rate. This suggests that CBL-514 may help maintain weight loss outcomes after GLP-1 therapy by directly targeting the root cause of subcutaneous fat through selective induction of adipocyte apoptosis. It has the potential to serve as a complementary combination therapy with GLP-1 treatments, providing both systemic weight loss and precise body contouring.

More on TelAve News

• Juego Studios Extends Full-Cycle Game Development & Outsourcing Capabilities to the UAE Market
• VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
• Atlanta Tech Founder Seeks Clarity on Intellectual Property and Innovation Policy
• Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy
• Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships

Caliway plans to submit an IND application for this new indication to the U.S. FDA in Q4 2025. CEO Vivian Ling believes that post-weight-loss weight rebound is a promising unmet market need and that CBL-514 has the potential to enhance the overall treatment impact and long-term value by reshaping and maintaining outcomes through localized fat reduction.

The BIO International Convention is the largest and most influential biotechnology event in the world, attracting over 20,000 professionals and 5,000 companies from 80+ countries. It serves as a global platform for business development, innovation exchange, and investment.

Caliway's presentation at BIO 2025 will take place on Tuesday, June 17 at 11:45 AM – 12:00 PM (EDT) in Room 154 at the Boston Convention & Exhibition Center. April Yuan, VP of Caliway Biopharmaceuticals, will be the speaker. More information about the session can be found on the convention's website.

CBL-514 is a first-in-class small-molecule drug developed by Caliway that targets subcutaneous fat without causing any systemic side effects on the central nervous system, cardiovascular system, or respiratory system. As of May 2025, it has completed 10 clinical trials with a total of 520 subjects and has met all efficacy and safety endpoints.

More on TelAve News

• Primeindexer Google indexing platform launched by SEO Danmark APS
• Kaltra Introduces New Downward-Spraying Distribution Technology to Boost Microchannel Evaporator Performance
• Talentica Announces Winners of Multi-Agent Hackathon 2026
• Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth
• Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX

Caliway is currently investigating multiple indications for CBL-514 including non-surgical fat reduction, moderate-to-severe cellulite, and weight rebound management through a combination therapy with GLP-1-based treatments. They are also studying CBL-514D for additional indications such as Dercum's disease.

Caliway Biopharmaceuticals (TWSE:6919) is a clinical-stage biopharmaceutical company focused on breakthrough drug discovery of novel small-molecule therapeutics. Their goal is to become an innovative leader in aesthetic medicine and other diseases. For more information about Caliway Biopharmaceuticals, please visit their website.

Disclaimer: This article and related information on this site contain forward-looking statements that are subject to risks and uncertainties. These statements are based on current expectations, estimates, and projections about the industry, markets in which Caliway operates, and management's beliefs and assumptions. Actual results may differ materially from those expressed or implied in these statements due to various factors. Caliway does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date of this article.

---

Show All News | Report Violation